Preclinical Development of EBI-005: An IL-1 Receptor-1 Inhibitor for the Topical Ocular Treatment of Ocular Surface Inflammatory Diseases

医学 药理学 免疫原性 体内 耐受性 药品 生物利用度 全身给药 药代动力学 受体拮抗剂 受体 敌手 免疫学 不利影响 内科学 抗体 生物 生物技术
作者
Joseph Kovalchin,Bracken M. King,Allyson Masci,Elizabeth Hopkins,Jeremy Fry,Jay Hou,Christian Li,Kelly Tenneson,Steve Weber,Gary W. Wolfe,Kathy Collins,Eric S. Furfine
出处
期刊:Eye & Contact Lens-science and Clinical Practice [Lippincott Williams & Wilkins]
卷期号:44 (3): 170-181 被引量:18
标识
DOI:10.1097/icl.0000000000000414
摘要

Objective: Topical interleukin (IL)-1 receptor (R)1 blockade is therapeutically active in reducing signs and symptoms of dry eye disease. Herein, we describe in vitro and in vivo nonclinical Investigational New Drug (IND)-enabling studies of EBI-005, a novel protein chimera of IL-1β and IL-1 receptor antagonist (IL-1Ra or anakinra) that potently binds IL-1R1 and blocks signaling. These studies provide an assessment of receptor affinity, drug bioavailability, immunogenic response, safety, and tolerability in mice and rabbits. Methods: In vitro and in silico along with Good Laboratory Practices (GLP) and non-GLP in vivo studies in mice and rabbits assessed the topical ocular and systemic immunogenicity and toxicology of EBI-005. Animals were treated with EBI-005 once daily subcutaneously or four times daily by topical ocular administration for up to 6 weeks (with 2-week recovery phase). Results: EBI-005 has 500 times higher affinity than anakinra to IL-1R1. Predictive immunogenicity testing suggested that EBI-005 is not more immunogenic. Systemic bioavailability of EBI-005 is low (1.4% in mice and 0.2% in rabbits) after topical ocular administration. EBI-005 penetrated into the anterior ocular tissues within 15 min of topical ocular administration. However, it is low or undetectable after 4 hr and does not form a depot after repeated topical ocular administration. EBI-005 was safe and well tolerated, and exposure to drug was maintained despite an antidrug antibody response after systemic administration, based on IND-enabling toxicology and safety pharmacology studies. Conclusions: Ocular doses of EBI-005 at 50 mg/mL in mice and rabbits totaling 0.15 mg/eye in mice and 1.5 mg/eye in rabbits, administered 4 times daily, did not produce adverse effects, and demonstrated excellent bioavailability in target tissues with low systemic exposure. In addition, immunogenic response to the drug did not cause adverse effects or diminish the drug's activity in most cases. The results support drug administration of the highest anticipated human clinical study dose of a 20 mg/mL solution (40 μL 3 times daily in each eye).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
忧虑的惜珊关注了科研通微信公众号
1秒前
1秒前
酒酿是也完成签到 ,获得积分10
1秒前
李琦完成签到 ,获得积分10
2秒前
2秒前
楚留香发布了新的文献求助10
2秒前
2秒前
时静发布了新的文献求助10
2秒前
科研通AI2S的应助被Molecular采纳,获得10
3秒前
cocoliu完成签到,获得积分10
3秒前
3秒前
3秒前
大胆妖孽完成签到,获得积分10
3秒前
晴日海风吹完成签到,获得积分10
3秒前
Jasper的应助被周周采纳,获得10
3秒前
3秒前
科研通AI6.3的应助被meiko采纳,获得10
5秒前
gaoyingxin完成签到,获得积分10
5秒前
5秒前
蓝月半完成签到,获得积分10
5秒前
5秒前
6秒前
taoyanhui发布了新的文献求助10
6秒前
嘿嘿发布了新的文献求助10
6秒前
sjx发布了新的文献求助10
7秒前
完美世界的应助被lhy采纳,获得10
7秒前
gaoyingxin发布了新的文献求助30
7秒前
小明同学发布了新的文献求助10
8秒前
yyc完成签到,获得积分20
8秒前
小蘑菇的应助被wzg666采纳,获得10
8秒前
半斤酒才完成签到,获得积分10
8秒前
老迟到的连虎完成签到,获得积分10
8秒前
lili发布了新的文献求助10
9秒前
酷酷的鸿完成签到,获得积分10
10秒前
Enfant发布了新的文献求助10
10秒前
10秒前
10秒前
张伟发布了新的文献求助10
10秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186261
求助须知:如何正确求助?哪些是违规求助? 9574697
关于积分的说明 21837731
捐赠科研通 7783915
什么是DOI,文献DOI怎么找? 3434752
关于科研通互助平台的介绍 2559109
邀请新用户注册赠送积分活动 2481528